RayKnowChina Research Map
Shortlist

JinhuaZhejiang University School of Medicine

Affiliated Jinhua Hospital of Zhejiang University

Listed for 3 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Affiliated Jinhua Hospital of Zhejiang University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Pancreatic cancer胰腺癌6 papers led
  2. Breast cancer乳腺癌19 papers led
  3. Glioma胶质瘤9 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Lung cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Pancreatic cancer

胰腺癌

Led 6 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 0020242025: 112025

1 hospital in Jinhua for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatologySurgery (general/hepatobiliary/pancreatic)

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 19 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
19
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 5520232024: 6620242025: 442025

1 hospital in Jinhua for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
    Phase
    N/A
    Started
    2023-07
    Posted
    Registry
    NCT07920094

    Age 18 years to 70 years; women only (registered criteria)

    Led by Sir Run Run Shaw Hospital; 10 listed hospitals as study sitesHangzhou, Jinhua, Ningbo, Taizhou, Wenzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncology

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led19
  1. Delineation of hub genes related to ferroptosis and radiosensitivity in breast cancer with three identified subtypes.2026Computer methods in biomechanics and biomedical engineering
  2. The tRF-33/IGF1 axis dysregulates mitochondrial homeostasis in HER2-negative breast cancer.2025American journal of physiology. Cell physiology
  3. Validation of in vivo dose using EPID combined with fan-beam CT guidance in post-breast-conserving radiotherapy for early-stage breast cancer.2025BMC cancerFree full text
  4. USP44 promotes chemotherapeutic drug resistance of triple negative breast cancer through EZH2 protein stability.2025Cancer biology & therapyFree full text
  5. A Breast Cancer Prognostic Model Based on Folic Acid Metabolism-Related Genes to Reveal the Immune Landscape.2025Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
  6. Prognostic Factors, Predictive Modeling, and Treatment Patterns in Breast Cancer Patients with Bone Metastasis Receiving First-Line Chemotherapy: A Population-Based Study.2024Annali italiani di chirurgia
  7. The global, regional, and national disease burden of breast cancer attributable to tobacco from 1990 to 2019: a global burden of disease study.2024BMC public healthFree full text
  8. Development of a breast cancer prognostic model based on vesicle-mediated transport-related genes to predict immune landscape and clinical drug therapy.2024Human molecular genetics
  9. Identification of Subtypes in Triple-negative Breast Cancer Based on Shared Genes Between Immunity and Cancer Stemness.2024Journal of immunotherapy (Hagerstown, Md. : 1997)
  10. Emerging role of necroptosis, pyroptosis, and ferroptosis in breast cancer: New dawn for overcoming therapy resistance.2024Neoplasia (New York, N.Y.)Free full text
  11. Successful treatment of Bowen's Disease in the nipple-areola complex with a combination of photodynamic therapy and cryotherapy-A case report.2024Photodiagnosis and photodynamic therapy
  12. Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer.2023Biomolecules & biomedicineFree full text
  13. Matrine exerts an anti-tumor effect via regulating HN1 in triple breast cancer both in vitro and in vivo.2023Chemical biology & drug design
  14. Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview.2023Frontiers in immunologyFree full text
  15. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.2023PloS oneFree full text
  16. Dysregulated ceRNA network modulated by copy number variation-driven lncRNAs in breast cancer: A comprehensive analysis.2023The journal of gene medicine
  17. Sesamol inhibits proliferation, migration and invasion of triple negative breast cancer via inactivating Wnt/β-catenin signaling.2022Biochemical pharmacology
  18. Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer.2022International journal of clinical oncology
  19. Sesamol Epigenetically Induces Estrogen Receptor α Re-expression by Upregulating miR-370-3p in Estrogen Receptor α-Negative Breast Cancer.2021Journal of agricultural and food chemistry
All its trials on ClinicalTrials.gov, any status1
  1. Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving SurgeryRecruitingNCT07920094Study siteN/AStart 2023-07

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 9 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 1120232024: 1120242025: 552025

1 hospital in Jinhua for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersNeurosurgeryPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

Affiliated Jinhua Hospital of Zhejiang University

金华

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

No hospital-level ROR record matched.

Suggest a correctionDownload the data